A drug delivery technology that once drew hundreds of millions in funding is getting a second chance. According to Endpoints News, Innoviva — described as a healthcare asset and royalties holding company — is reviving Lyndra's long-acting oral drug platform, bringing the approach back to life after the company behind it had stalled.
The appeal of long-acting oral medicines is straightforward: instead of taking a pill every day, a patient could swallow a single dose designed to release medication slowly over an extended period. That kind of "take it and forget it" delivery can be especially valuable for chronic conditions, where missed daily doses are a common and costly problem.
Endpoints News reports that the platform had accumulated more than $380 million in venture and nonprofit funding. That figure underscores both how much investor and philanthropic conviction the technology attracted, and how much money was at risk of being written off when the original effort lost momentum.
The source frames Innoviva's move as a resurrection — picking up a drug delivery system that had been developed but not carried across the finish line. As a holding company focused on assets and royalties, Innoviva is positioned to acquire and steward such technologies rather than necessarily inventing them from scratch.
Why it matters: reviving a platform with this much prior backing signals that the long-acting oral delivery idea is too promising to abandon — and if it succeeds, it could make daily medication routines dramatically simpler for patients managing long-term illness.